Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction.

Berberine, a natural product, has been widely used to treat hyperlipoidemia and intestinal diseases. In the present paper, berberine showed a significant anti-proliferative effect to human cervical carcinoma HeLa cells confirmed by 3-(4,5)-dimethyl-thiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT), flow cytometry analysis (FCM) and so on. The methods including western blotting, radioimmunity assay (RIA), reverse transcription-polymerase chain reaction (RT-PCR) were used to investigate protein and mRNA expressions. We found that Bcl-2/Bax ratio was significantly decreased and cytochrome c was released from mitochondrion to cytosol, which indicated that the mitochondrial pathway was activated by berberine. The up-regulation of Fas, FasL, TNF-alpha and TRAF-1 indicated the involvement of the death receptor pathway in the process of berberine-induced apoptosis. Furthermore caspase-3 and caspase-8 were activated as a central event of apoptosis, and the levels of phosphorylation of mitogen-activated protein kinases (MAPKs) were also investigated. In addition, the increased expression of p53 was also observed in berberine-treated HeLa cells, and as a node point of these different pathways in a protein-protein interaction network constructed by GeneGo software, p53 might be the possible drug-target of berberine's anti-cancer on HeLa cells, which was predicted by a flexible ligand-protein inverse docking program, INVDOCK. This study is benefit for clarifying the mechanism of berberine's anti-tumor effect and might be helpful to find therapy-target for treatment of human cervical carcinoma.

[1]  C. Trautwein,et al.  Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. , 2006, Cancer research.

[2]  Jeong Eon Lee,et al.  Berberine Suppresses TNF-α-induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells , 2008, Molecules.

[3]  S. Katiyar,et al.  Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. , 2008, Toxicology and applied pharmacology.

[4]  S. Tsao,et al.  Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. , 2009, Journal of ethnopharmacology.

[5]  G. Melino,et al.  TAp63α induces apoptosis by activating signaling via death receptors and mitochondria , 2005, The EMBO journal.

[6]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[7]  A. Roulston,et al.  Early Activation of c-Jun N-terminal Kinase and p38 Kinase Regulate Cell Survival in Response to Tumor Necrosis Factor α* , 1998, The Journal of Biological Chemistry.

[8]  K. Ketiku,et al.  Chemotherapy of breast cancer in Nigerians: side-effects and quality of life. , 1990, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  B. Y. Chin,et al.  Mitogen-activated protein kinase pathway mediates hyperoxia-induced apoptosis in cultured macrophage cells. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[10]  De-An Guo,et al.  Proteomics Characterization of the Cytotoxicity Mechanism of Ganoderic Acid D and Computer-automated Estimation of the Possible Drug Target Network*S , 2008, Molecular & Cellular Proteomics.

[11]  P. Schwartzkroin,et al.  Evidence for p53-Mediated Modulation of Neuronal Viability , 1996, The Journal of Neuroscience.

[12]  O. Frankfurt,et al.  Apoptosis-based drug screening and detection of selective toxicity to cancer cells , 2003, Anti-cancer drugs.

[13]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[14]  Zhou Jian.  IMPROVED MTT ASSAY FOR ACTIVITY OF ANTITUMOR AGENTS , 1993 .

[15]  Kuang-Chi Lai,et al.  Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. , 2009, Cancer letters.

[16]  C. Rescan,et al.  The Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Cascade Activation Is a Key Signalling Pathway Involved in the Regulation of G1 Phase Progression in Proliferating Hepatocytes , 1999, Molecular and Cellular Biology.

[17]  C. Vogel,et al.  High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. , 2009, Clinical therapeutics.

[18]  L. Cipak,et al.  Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells , 2003, The Journal of pharmacy and pharmacology.

[19]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[20]  N. Banik,et al.  Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH‐SY5Y cells exposed to flavonoids , 2006, International journal of cancer.

[21]  S. Letašiová,et al.  Effect of berberine on proliferation, biosynthesis of macromolecules, cell cycle and induction of intercalation with DNA, dsDNA damage and apoptosis in Ehrlich ascites carcinoma cells , 2006, The Journal of pharmacy and pharmacology.

[22]  Swati Sinha,et al.  Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases , 2006, The Prostate.

[23]  J. Han.  Traditional Chinese medicine and the search for new antineoplastic drugs. , 1988, Journal of ethnopharmacology.

[24]  M. Karin,et al.  Inhibition of JNK activation through NF-κB target genes , 2001, Nature.

[25]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[26]  Michael Karin,et al.  Reactive Oxygen Species Promote TNFα-Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases , 2005, Cell.

[27]  D. Lee,et al.  Reactive oxygen species up‐regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin , 2009, British journal of pharmacology.

[28]  J. Bradbury.  From Chinese medicine to anticancer drugs. , 2005, Drug discovery today.

[29]  Jang-Yang Chang,et al.  Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. , 2007, Biochemical pharmacology.

[30]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[31]  Francesca Zazzeroni,et al.  Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling , 2001, Nature.

[32]  L. Damon,et al.  The metabolic basis for combination chemotherapy. , 1988, Pharmacology & therapeutics.

[33]  K. Todokoro,et al.  Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. , 1999, Blood.

[34]  J C Reed,et al.  Apoptosis-regulating proteins as targets for drug discovery. , 2001, Trends in molecular medicine.

[35]  Seung Joon Baek,et al.  Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. , 2007, Cancer letters.

[36]  S. Chung,et al.  Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. , 2008, Biological & pharmaceutical bulletin.

[37]  Longgui Wang,et al.  The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review , 1999, Cancer Chemotherapy and Pharmacology.

[38]  Silvia Letasiová,et al.  Antiproliferative activity of berberine in vitro and in vivo. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.